This option is particularly relevant as a phase 1/2 clinical trial with a humanized ADC directed against uPARAP, including a payload belonging to this class, has been recently initiated with soft tissue sarcomas as the primary indication (ClinicalTrials.gov ID: NCT06797999). Here, MRC2 is linked to soft tissue sarcoma.